Is Pharming Group Stock a Good Investment?
Pharming Group Investment Advice | PHAR |
- Examine Pharming Group's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Pharming Group's leadership team and their track record. Good management can help Pharming Group navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Pharming Group's business and its evolving consumer preferences.
- Compare Pharming Group's performance and market position to its competitors. Analyze how Pharming Group is positioned in terms of product offerings, innovation, and market share.
- Check if Pharming Group pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Pharming Group's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pharming Group NV stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pharming Group NV is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Pharming Group Stock
Researching Pharming Group's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was at this time reported as 0.44. The company recorded a loss per share of 0.27. Pharming Group NV had not issued any dividends in recent years.
To determine if Pharming Group is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pharming Group's research are outlined below:
| Pharming Group NV had very high historical volatility over the last 90 days | |
| Pharming Group NV has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 245.32 M. Net Loss for the year was (9.55 M) with profit before overhead, payroll, taxes, and interest of 188.06 M. | |
| Pharming Group NV currently holds about 189.96 M in cash with (17.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91. | |
| Pharming Group NV has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Pharming Group to participate in November investor conference |
Pharming Group Quarterly Liabilities And Stockholders Equity |
|
Pharming Group uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pharming Group NV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pharming Group's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Pharming Group's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pharming Group's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-24 | 2024-09-30 | -0.0025 | -0.0153 | -0.0128 | 512 | ||
2022-03-17 | 2021-12-31 | 0.03 | 0.015 | -0.015 | 50 | ||
2024-08-01 | 2024-06-30 | -0.002 | -0.0177 | -0.0157 | 785 | ||
2021-05-13 | 2021-03-31 | 0.1385 | 0.157 | 0.0185 | 13 | ||
2021-03-04 | 2020-12-31 | 0.0844 | 0.1144 | 0.03 | 35 | ||
2021-10-28 | 2021-09-30 | 0.0414 | -5.0E-4 | -0.0419 | 101 | ||
2024-03-14 | 2023-12-31 | 0.0045 | -0.0406 | -0.0451 | 1002 | ||
2023-05-11 | 2023-03-31 | -0.065 | -0.17 | -0.105 | 161 |
Know Pharming Group's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pharming Group is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pharming Group NV backward and forwards among themselves. Pharming Group's institutional investor refers to the entity that pools money to purchase Pharming Group's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Silverberg Bernstein Capital Management Llc | 2024-09-30 | 41.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 5.6 K | Ubs Group Ag | 2024-06-30 | 789 | Advisor Group Holdings, Inc. | 2024-06-30 | 568 |
Pharming Group's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 520.98 M.Market Cap |
|
Pharming Group's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | (0.05) | (0.05) |
Determining Pharming Group's profitability involves analyzing its financial statements and using various financial metrics to determine if Pharming Group is a good buy. For example, gross profit margin measures Pharming Group's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pharming Group's profitability and make more informed investment decisions.
Evaluate Pharming Group's management efficiency
Pharming Group NV has return on total asset (ROA) of (0.0138) % which means that it has lost $0.0138 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0818) %, meaning that it created substantial loss on money invested by shareholders. Pharming Group's management efficiency ratios could be used to measure how well Pharming Group manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to drop to -0.03. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Pharming Group's Asset Turnover is relatively stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.33 | 3.16 | |
| Tangible Book Value Per Share | 2.25 | 3.47 | |
| Enterprise Value Over EBITDA | 87.15 | 91.51 | |
| Price Book Value Ratio | 3.43 | 5.17 | |
| Enterprise Value Multiple | 87.15 | 91.51 | |
| Price Fair Value | 3.43 | 5.17 | |
| Enterprise Value | 860.8 M | 903.8 M |
Evaluating the management effectiveness of Pharming Group allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Pharming Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 0.811 |
Basic technical analysis of Pharming Stock
As of the 22nd of November, Pharming Group holds the Semi Deviation of 3.44, risk adjusted performance of 0.0143, and Coefficient Of Variation of 11555.86. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pharming Group, as well as the relationship between them. Please check Pharming Group NV standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Pharming Group NV is priced some-what accurately, providing market reflects its current price of 7.76 per share. Given that Pharming Group has jensen alpha of 0.0524, we recommend you to check out Pharming Group NV's recent market performance to make sure the company can sustain itself at a future point.Pharming Group's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pharming Group insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pharming Group's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pharming Group insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Camden Partners Strategic Fund Ii A Lp over three months ago Acquisition by Camden Partners Strategic Fund Ii A Lp of 5000 shares of Pharming Group at 0.68 subject to Rule 16b-3 |
Pharming Group's Outstanding Corporate Bonds
Pharming Group issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pharming Group NV uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pharming bonds can be classified according to their maturity, which is the date when Pharming Group NV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| PHARMACIA P 66 Corp BondUS71713UAW27 | View | |
| PHARMACIA P 675 Corp BondUS71713UAT97 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Pharming Group's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Pharming Group's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0143 | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 2.73 | |||
| Semi Deviation | 3.44 | |||
| Downside Deviation | 3.55 | |||
| Coefficient Of Variation | 11555.86 | |||
| Standard Deviation | 3.38 | |||
| Variance | 11.46 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | 0.0524 | |||
| Total Risk Alpha | (0.36) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 13.75 | |||
| Value At Risk | (5.60) | |||
| Potential Upside | 5.19 | |||
| Downside Variance | 12.62 | |||
| Semi Variance | 11.8 | |||
| Expected Short fall | (2.76) | |||
| Skewness | (0.16) | |||
| Kurtosis | (0.51) |
| Risk Adjusted Performance | 0.0143 | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 2.73 | |||
| Semi Deviation | 3.44 | |||
| Downside Deviation | 3.55 | |||
| Coefficient Of Variation | 11555.86 | |||
| Standard Deviation | 3.38 | |||
| Variance | 11.46 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | 0.0524 | |||
| Total Risk Alpha | (0.36) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 13.75 | |||
| Value At Risk | (5.60) | |||
| Potential Upside | 5.19 | |||
| Downside Variance | 12.62 | |||
| Semi Variance | 11.8 | |||
| Expected Short fall | (2.76) | |||
| Skewness | (0.16) | |||
| Kurtosis | (0.51) |
Consider Pharming Group's intraday indicators
Pharming Group intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pharming Group stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pharming Group Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
6K | 24th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 4th of April 2024 Other Reports | ViewVerify |
Pharming Stock media impact
Far too much social signal, news, headlines, and media speculation about Pharming Group that are available to investors today. That information is available publicly through Pharming media outlets and privately through word of mouth or via Pharming internal channels. However, regardless of the origin, that massive amount of Pharming data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pharming Group news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pharming Group relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pharming Group's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pharming Group alpha.
Pharming Group Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Pharming Group can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pharming Group Corporate Management
| Bruno Giannetti | Consultant | Profile | |
| Susanne Embleton | Investor Manager | Profile | |
| Jeroen Wakkerman | Chief Officer | Profile | |
| Ruud Outersterp | Chief Officer | Profile | |
| Stephen Toor | Chief Americas | Profile | |
| Anurag Relan | Chief Officer | Profile |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.